ecrin-mdr-crcClinical2020Uterine Cervical NeoplasmsSolid TumorCarcinomaCervical CancerMelanomaMesotheliomaCutaneous Squamous Cell CarcinomaOropharynx CancerCarcinoma, Squamous CellSquamous Cell Carcinoma of Head and NeckMicrosatellite Stable Colorectal CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaMelanoma (Skin)Mesothelioma, MalignantRenal Cell CarcinomaOropharyngeal NeoplasmsUterine Cervical NeoplasmsSolid TumorCarcinomaCervical CancerMelanomaMesotheliomaCutaneous Squamous Cell CarcinomaOropharynx CancerCarcinoma, Squamous CellSquamous Cell Carcinoma Of Head And NeckMicrosatellite Stable Colorectal CancerMelanoma (skin)Mesothelioma, MalignantRenal Cell CarcinomaHpv Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2332523CanadaSouth KoreaUnited States6OropharyngealPembrolizumabHPV cancerCRCOncolytic VirusMSS-CRCIntratumoral injectionRenal CellSkin cancerECRIN MDRActive, not recruitingfalseStudy of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTo determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).2020-06-152332523NCT04301011